(rac)-Lomedeucitinib
Based on 1 Customer Validation
(rac)-Lomedeucitinib ((rac)-BMS-986322) is the racemate of Lomedeucitinib. Lomedeucitinib (BMS-986322) is a tyrosine protein kinase (TYK2) inhibitor. Lomedeucitinib has anti-inflammatory activity and significant inhibitory effect on IFNα (IC50=0.047 μM) production downstream of IL-12/TYK2. Lomedeucitinib is indicated for the study of plaque psoriasis and pruritus.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.11%
- CAS No.: 2328064-33-9
- Formule: C18H17D3N6O4S
- Masse moléculaire:419.47
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
CAS No. 2328064-33-9
-
Appearance Solid
-
Masse moléculaire 419.47
-
Formule C18H17D3N6O4S
-
Color White to off-white
-
SMILES
O=C(C1=NN=C(NC(C2CC23CC3)=O)C=C1NC4=NC=CC=C4S(=O)(C)=O)NC([2H])([2H])[2H]
-
Synonyms
(rac)-BMS-986322
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Pureté et documentation
-
Fiche technique (271 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Drakos A, et al. Emerging Oral Therapies for the Treatment of Psoriasis: A Review of Pipeline Agents[J]. Pharmaceutics, 2024, 16(1): 111. [Content Brief]
[2]. Zhang K, et al. Development and therapeutic implications of tyrosine kinase 2 inhibitors[J]. Journal of Medicinal Chemistry, 2023, 66(7): 4378-4416. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
(rac)-Lomedeucitinib Related Classifications
HY-160144S2 Related Classifications
Powered by Bioz